Wall Street brokerages expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report ($0.16) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Achillion Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.14). Achillion Pharmaceuticals posted earnings of ($0.15) per share in the same quarter last year, which would indicate a negative year over year growth rate of 6.7%. The business is scheduled to announce its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.67) per share for the current year, with EPS estimates ranging from ($0.79) to ($0.55). For the next year, analysts anticipate that the business will report earnings of ($0.76) per share, with EPS estimates ranging from ($1.00) to ($0.51). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same quarter in the previous year, the business posted ($0.03) earnings per share.
Achillion Pharmaceuticals (NASDAQ:ACHN) remained flat at $$2.95 on Monday. 1,540,300 shares of the company were exchanged, compared to its average volume of 2,131,218. Achillion Pharmaceuticals has a 1-year low of $2.58 and a 1-year high of $5.66. The stock has a market capitalization of $472.85, a price-to-earnings ratio of -4.76 and a beta of 1.32.
A number of hedge funds and other institutional investors have recently modified their holdings of ACHN. Teacher Retirement System of Texas bought a new position in Achillion Pharmaceuticals during the 4th quarter valued at $109,000. Bourgeon Capital Management LLC boosted its stake in Achillion Pharmaceuticals by 64.4% during the 4th quarter. Bourgeon Capital Management LLC now owns 48,504 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 19,004 shares in the last quarter. MetLife Investment Advisors LLC bought a new position in Achillion Pharmaceuticals during the 4th quarter valued at $162,000. SG Americas Securities LLC boosted its stake in Achillion Pharmaceuticals by 59.8% during the 3rd quarter. SG Americas Securities LLC now owns 42,229 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 15,800 shares in the last quarter. Finally, BlueCrest Capital Management Ltd bought a new position in Achillion Pharmaceuticals during the 4th quarter valued at $209,000. 78.75% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3223468/3223468.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.